Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance

Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and 
Provides 2014 Guidance 
Horizon to Host Conference Call / Webcast Today at 8:00 a.m. EST 
DEERFIELD, IL -- (Marketwired) -- 11/19/13 --  Horizon Pharma, Inc.
(NASDAQ: HZNP) today announced that it has entered into an agreement
to acquire from AstraZeneca AB the U.S. rights to VIMOVO(R)
(naproxen/esomeprazole magnesium) delayed-release tablets, further
expanding Horizon's focus on key primary care physician targets in
the U.S. VIMOVO is approved in the U.S. to relieve the signs and
symptoms of osteoarthritis, rheumatoid arthritis and ankylosing
spondylitis and to decrease the risk of stomach (gastric) ulcers in
patients at risk of developing stomach ulcers from treatment with
NSAIDs. AstraZeneca will retain ex-U.S. rights to VIMOVO. 
"The acquisition of VIMOVO is a major step forward in our strategy to
leverage our business model and maximize our commercial
infrastructure and we expect it to create significant value for our
shareholders," stated Timothy P. Walbert, chairman, president and
chief executive officer of Horizon. "We anticipate that this
transaction will significantly increase our revenues and accelerate
the Company to profitable operations."  
Expected Benefits of Transaction 

--  Leverages the Company's existing commercial infrastructure.
--  Expected to accelerate the Company's time to profitability.
--  Expected to be accretive to non GAAP net income in 2014.

Full-year 2014 Guidance 

--  The Company expects 2014 full-year net revenue of $190 to $205
--  The Company expects to be profitable in 2014 on a non GAAP basis,
    based on Horizon's prior GAAP to non GAAP reconciliation practice.
--  The Company expects that existing cash at September 30, 2013, of $58.7
    million, along with the net proceeds from an offering of convertible
    senior unsecured notes of approximately $19.7 million, will fund it to
    cash flow positive operations.

Transaction Details 

--  The Company will make a one-time upfront payment of $35 million to
    AstraZeneca for the U.S. rights to VIMOVO and will pay a 10% royalty
    on net sales to Pozen, subject to annual minimum royalties of $5
    million in 2014 and $7.5 million each year thereafter, provided that
    the patents owned by Pozen which cover VIMOVO remain in effect and no
    generic forms of VIMOVO are on the market.
--  For the remainder of the fourth quarter of 2013, AstraZeneca will
    continue to distribute and book revenues for VIMOVO and Horizon will
    receive any related net profits from AstraZeneca.

Operational Plan 

--  The Company expects to begin sales of VIMOVO early in the first
    quarter of 2014.
--  The Company plans to expand its primary care sales force from 150
    representatives to approximately 250 sales representatives, with
    representatives promoting DUEXIS(R) and VIMOVO to specific targets,
    with approximately 30% overlap in targets for both DUEXIS and VIMOVO.
--  The Company will expand its rheumatology specialty sales force from 25
    representatives to approximately 40 representatives, with
    representatives promoting RAYOS(R) and VIMOVO to rheumatologists.
--  The Company plans to include VIMOVO in the Company's
    Prescriptions-Made-Easy(TM) specialty pharmacy program to ensure
    patients receive VIMOVO at a reasonable out-of-pocket cost.
--  The Company expects to price VIMOVO in line with DUEXIS and other
    branded NSAIDs when it begins selling VIMOVO.
--  The Company expects gross-to-net sales deductions of VIMOVO to be
    between 35% and 40%.

JMP Securities LLC acted as financial advisor and Cooley LLP acted as
legal advisor to the Company on the VIMOVO acquisition. 
Investor Conference Call / Webcast Information 
At 8:00 a.m. Eastern Time today, Horizon's management will host a
live conference call and webcast to provide further information on
this announcement.  
The live webcast and a replay may be accessed by visiting Horizon's
website at http://ir.horizon-pharma.com. Please connect to the
Company's website at least 15 minutes prior to the live webcast to
ensure adequate time for any software download that may be needed to
access the webcast. Alternatively, please call 1-888-338-8373 (U.S.)
or 973-872-3000 (international) to listen to the conference call. The
conference ID number for the live call is 13405454. Telephone replay
will be available approximately two hours after the call. To access
the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406
(international). The conference ID number for the replay is 13405454. 
About Horizon Pharma 
Horizon Pharma, Inc. is a specialty pharmaceutical company that has
developed and is commercializing products to primary care, orthopedic
surgeons and rheumatologists. The Company markets DUEXIS(R) and
RAYOS(R)/LODOTRA(R) and will market VIMOVO(R), which target unmet
therapeutic needs in arthritis, pain and inflammatory diseases. The
Company's strategy is to develop, acquire or in-license additional
innovative medicines where it can execute a targeted commercial
approach among specific target physicians while taking advantage of
its commercial strengths and the infrastructure the Company has put
in place. For more information, please visit www.horizonpharma.com. 
VIMOVO(R) (naproxen / esomeprazole magnesium) is a proprietary
fixed-dose combination of delayed-release enteric-coated naproxen, a
non-steroidal anti-inflammatory drug (NSAID) and immediate-release
esomeprazole, a stomach acid-reducing proton pump inhibitor (PPI),
approved for the relief of signs and symptoms of osteoarthritis,
rheumatoid arthritis and ankylosing spondylitis and to decrease the
risk of developing gastric ulcers in patients at risk of developing
NSAID-associated gastric ulcers. VIMOVO is not recommended for use in
children younger than 18 years of age. VIMOVO is not recommended for
initial treatment of acute pain because the absorption of naproxen is
delayed compared to absorption from other naproxen-containing
products. Controlled studies do not extend beyond 6 months. VIMOVO
should be used at the lowest dose and for the shortest amount of time
as directed by your health care provider. 
For Full Prescribing Information see www.VIMOVO.com.  
Forward Looking Statements 
This press release contains forward-looking statements, including
statements regarding the expected acquisition of the U.S. rights to
VIMOVO, the anticipated benefits of the acquisition, including
potential shareholder value creation and impact on Horizon's future
financial results, Horizon's plans and expectations with respect to
its commercialization of VIMOVO in the United States, including
planned increases in its field sales force, and Horizon's
expectations with respect to 2014 revenue and time to profitability.
These forward-looking statements are based on management's
expectations and assumptions as of the date of this press release and
actual results may differ materially from those in these
forward-looking statements as a result of various factors. These
factors include, but are not limited to risks regarding the closing
of the acquisition, Horizon's ability to commercialize its products
successfully, the impact of pricing decisions on product revenues,
Horizon's ability to successfully hire and manage contract sales and
marketing personnel, Horizon's ability to comply with post-approval
regulatory requirements, Horizon's ability to increase revenues to
offset increases in expenses as a result of the VIMOVO acquisition,
the outcome of on-going and potential future patent litigation with
respect to Horizon's products, including VIMOVO, and Horizon's
ability to satisfy the closing conditions for the VIMOVO acquisition.
For a further description of these and other risks facing the
Company, please see the risk factors described in the Company's
filings with the United States Securities and Exchange Commission,
including those factors discussed under the caption "Risk Factors" in
those filings. Forward-looking statements speak only as of the date
of this press release and the Company undertakes no obligation to
update or revise these statements, except as may be required by law. 
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
Justin Jackson
Burns McClellan, Inc.
Press spacebar to pause and continue. Press esc to stop.